Efficacy of monoclonal antibody anti CD20 in extranodal minimal residual disease eradication

被引：0
|
作者：
Petrilli, M. P.
Cinieri, S.
Giordano, G.
Ruggiero, T.
Cavotta, S.
Capussela, E.
Ferrandina, C.
Gasbarrino, C.
Fraticelli, V.
Monaco, M.
Storti, S.
机构：
[1] Univ Cattolica Sacro Cuore, Ctr Ric & Formaz Alta Tecnol Sci Biomed, Unit Operat Oncoematol, Sede Campobasso, Italy
[2] Univ OORR, UO Ematol Azienda Mista Osped, Foggia, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [31] Eradication of minimal residual disease in patients with follicular lymphoma depends on the disease status and the type of cytotoxic therapy combined with the anti-CD20 monoclonal antibody (Rituximab) as revealed by molecular monitoring with nested and real-time PCR.
    Martin, S
    Fischer, C
    Niederste-Hollenberg, A
    Free, M
    Meckenstock, G
    Haas, R
    Kronenwett, R
    BLOOD, 2002, 100 (11) : 360A - 360A
  • [32] The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
    Teeling, Jessica L.
    Mackus, Wendy J. M.
    Wiegman, Luus J. J. M.
    van den Brakel, Jeroen H. N.
    Beers, Stephen A.
    French, Ruth R.
    van Meerten, Tom
    Ebeling, Saskia
    Vink, Tom
    Slootstra, Jerry W.
    Parren, Paul W. H. I.
    Glennie, Martin J.
    van de Winkel, Jan G. J.
    JOURNAL OF IMMUNOLOGY, 2006, 177 (01): : 362 - 371
  • [33] Anti-CD20-monoclonal-antibody/immune-globulinLack of efficacy: case report
    Reactions Weekly, 2022, 1917 (1) : 56 - 56
  • [34] Response to anti CD20 monoclonal antibody Rituximab® and epitope mapping of inhibitory antibodies in patients with acquired haemophilia.
    Krause, Manuela
    Koenigs, Christoph
    Kessel, Christoph
    Scharrer, Inge
    Grossmann, Ralf
    Kreuz, Wolfhard
    BLOOD, 2006, 108 (11) : 310A - 311A
  • [35] TG20, a Transgenically-Derived Anti-CD20 Monoclonal Antibody, Exhibits Enhanced Cytotoxicity Against Cells with Low Levels of CD20
    Echelard, Yann
    Pollock, Daniel P.
    De Coupade, Catherine
    Olivier, Aurelie Groseil
    Brune, Frederique
    Chen, LiHow
    Masiello, Nicholas C.
    Williams, Jennifer L.
    Gavin, William G.
    Chtourou, Sami
    Meade, Harry M.
    BLOOD, 2011, 118 (21) : 1174 - 1174
  • [36] Short term in vivo activity of Rituximab anti CD20 monoclonal antibody in B-CLL patients.
    Berchem, GJ
    Heintz, D
    Bosseler, M
    Duhem, C
    Ries, F
    Dicato, MA
    BLOOD, 1999, 94 (10) : 307B - 307B
  • [37] Response to: Monoclonal antibodies targeting CD20
    Klein, Christian
    Lammens, Alfred
    Schaefer, Wolfgang
    Georges, Guy
    Schwaiger, Manfred
    Moessner, Ekkehard
    Hopfner, Karl-Peter
    Umana, Pablo
    Niederfellner, Gerhard
    MABS, 2013, 5 (03) : 337 - 338
  • [38] Ofatumumab: a novel monoclonal anti-CD20 antibody
    Lin, Thomas S.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2010, 3 : 51 - 59
  • [39] Anti-CD20 monoclonal antibody in autoimmune diseases
    Pogliani, EM
    Larocca, A
    BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 (07) : 350 - 351
  • [40] Ofatumumab, a human anti-CD20 monoclonal antibody
    Osterborg, Anders
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (03) : 439 - 449
12345